O Shaughnessy Asset Management LLC Buys 27,035 Shares of Amgen Inc. $AMGN

O Shaughnessy Asset Management LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 25.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 132,386 shares of the medical research company’s stock after acquiring an additional 27,035 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Amgen were worth $43,331,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Anfield Capital Management LLC boosted its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its stake in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Board of the Pension Protection Fund bought a new position in Amgen during the fourth quarter worth $26,000. Manning & Napier Advisors LLC boosted its stake in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new position in Amgen during the fourth quarter worth $33,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Amgen stock opened at $349.58 on Monday. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The firm has a market capitalization of $188.67 billion, a price-to-earnings ratio of 24.33, a price-to-earnings-growth ratio of 3.51 and a beta of 0.42. The firm’s fifty day moving average price is $341.35 and its two-hundred day moving average price is $345.49. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the firm earned $4.90 earnings per share. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on AMGN. Leerink Partners reissued a “market perform” rating and set a $355.00 target price on shares of Amgen in a research note on Thursday, March 5th. Jefferies Financial Group began coverage on shares of Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. Guggenheim cut their target price on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research note on Monday, May 4th. Daiwa Securities Group cut their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Finally, Piper Sandler dropped their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $353.81.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.